Trial
NCT01394003
A Study of LY2584702 in Participants With Advanced Cancer
Phase ITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Eli Lilly and Company
Collaborators
—
Condition
Advanced Cancer
Intervention
LY2584702
Why stopped
The pharmacokinetic properties of the molecule do not allow for further dose escalation or development.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2019-01-18